Elite in Histiocytosis

Elena Sieni

Florence, IT 
Elite in Histiocytosis
Florence, IT 
OverviewLocationsClinical Research

Overview

Elena Sieni practices in Florence, Italy. Ms. Sieni is rated as an Elite expert by MediFind in the treatment of Histiocytosis. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 53 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 43 articles and participated in 2 clinical trials in the study of Histiocytosis.

Gender
Female

Locations

Florence, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

52 Total Publications

The novel XIAP Lys396Ter variant alters mitochondrial membrane potential and endoplasmic reticulum intensity in monocytes of two XIAP-deficient patients.
The novel XIAP Lys396Ter variant alters mitochondrial membrane potential and endoplasmic reticulum intensity in monocytes of two XIAP-deficient patients.
Journal: Pediatric hematology and oncology
Published: June 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sieni's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile